Sparsentan
Filspari (sparsentan) is a small molecule pharmaceutical. Sparsentan was first approved as Filspari on 2023-02-17. It is used to treat proteinuria in the USA. The pharmaceutical is active against type-1 angiotensin II receptor and endothelin-1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Filspari
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sparsentan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FILSPARI | Travere Therapeutics | N-216403 RX | 2023-02-17 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| daranjo | OTC monograph not final | 2020-09-07 |
| daraprim | New Drug Application | 2023-12-07 |
| darzalex | Biologic Licensing Application | 2021-09-10 |
| darzalex darzalex iv | Biologic Licensing Application | 2025-04-15 |
| darzalex faspro | Biologic Licensing Application | 2025-11-26 |
| filspari | New Drug Application | 2025-08-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| proteinuria | — | D011507 | R80 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SPARSENTAN, FILSPARI, TRAVERE | |||
| 2030-02-17 | ODE-389 | ||
| 2028-02-17 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sparsentan, Filspari, Travere | |||
| 9993461 | 2030-03-29 | U-3269 | |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
93 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | 3 | 1 | 1 | — | 5 |
| Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | — | 2 | 1 | 1 | — | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | — | 1 | — | 3 |
| Proteinuria | D011507 | — | R80 | 1 | — | — | 1 | — | 2 |
| Kidney transplantation | D016030 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vasculitis | D014657 | EFO_0006803 | M31 | — | 2 | — | — | — | 2 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 1 | — | — | — | 1 |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | — | 1 | — | — | — | 1 |
| Hereditary nephritis | D009394 | EFO_0004128 | Q87.81 | — | 1 | — | — | — | 1 |
| Lipoid nephrosis | D009402 | EFO_1001020 | N04 | — | 1 | — | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Anti-neutrophil cytoplasmic antibody-associated vasculitis | D056648 | — | I77.82 | — | 1 | — | — | — | 1 |
| Glomerulonephritis | D005921 | — | N05 | — | 1 | — | — | — | 1 |
| Immune system diseases | D007154 | — | D89.9 | — | 1 | — | — | — | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sparsentan |
| INN | sparsentan |
| Description | Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. Sparsentan is an endothelin and angiotensin II receptor antagonist. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | endothelin receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1 |
Identifiers
| PDB | — |
| CAS-ID | 254740-64-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL539423 |
| ChEBI ID | — |
| PubChem CID | 10257882 |
| DrugBank | DB12548 |
| UNII ID | 9242RO5URM (ChemIDplus, GSRS) |
Target
Agency Approved
AGTR1
AGTR1
EDNRA
EDNRA
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Filspari – Travere Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Filspari – Ligand Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Darzalex – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,149 documents
View more details
Safety
Black-box Warning
Black-box warning for: Filspari
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
72,504 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use